CAR-T Leader Sidansai Biotech Completes RMB 180 Million Series B Funding Led by Summit Healthcare Investment

VCBeat (WeChat ID: vcbeat) has learned that Shanghai Standard Cell Biotechnology Co., Ltd. (“Standard Cell Bio”) recently announced the completion of its Series B financing round, raising RMB 180 million, with GTJA Investment leading the round.

Leading CAR-T Enterprise in China

"Running Neck and Neck with the United States"

Since its establishment in 2009, Stance Bioscience has been committed to becoming a global leader in the field of cell therapy, primarily engaged in the research and application of cutting-edge CAR-T technology, gene editing technology, and stem cell technology.

Stanse Biotech’s CD19 CAR-T therapy for advanced acute lymphoblastic leukemia has undergone clinical trials in 39 patients at the hematology departments of more than ten top-tier Grade A tertiary hospitals across China since 2014, achieving a complete remission rate of 84.6% and an MRD negativity rate of 80%, reaching internationally leading standards. Moreover, Stanse Biotech’s CAR-T therapy for lymphoma has also achieved success, and clinical trials targeting solid tumors such as breast cancer and pancreatic cancer have been initiated at multiple hospitals.

These advancements have positioned Standard Biologics as a leader in China’s CAR-T sector, driving the development of China’s CAR-T field to a status of “parallel advancement” with that of the United States.

Hope to release

The Threat of Tumors to Human Health

“Stem Cell Therapy Biotech has achieved significant breakthroughs in the R&D of multiple indications for hematologic malignancies and solid tumors. This round of financing will provide strong support for the smooth advancement of the next phase of clinical trials,” said Dr. Xiao Lei, Founder and Chairman of Stem Cell Therapy Biotech.

(Dr. Xiao Lei communicates with researchers; photo provided by the company)

Regarding the development roadmap of Stance Bio, Dr. Xiao Lei stated, “The efficacy of CAR-T therapy in clinical trials is evident to all. We aim to achieve comprehensive breakthroughs in applying CAR-T technology to solid tumors and allogeneic treatments through the synergistic development of CAR-T with gene editing and stem cell technologies. We hope that Stance Bio can make substantial contributions to alleviating the threat cancer poses to human health.”

Stancey Bio’s Innovative Product Pipeline

Established Competitive Barriers

Cai Dajian, Founder and Chairman of GTJA Investment Group, stated that with the successive international approvals and market launches of CAR-T products, along with the issuance of relevant policies on cellular products by the China Food and Drug Administration (CFDA), the CAR-T industry has truly ushered in a new era. Through years of dedicated research and accumulation, St. Science Biotech has developed breakthrough cell therapy products and established comprehensive production and quality control systems, positioning itself at the forefront of China’s CAR-T industry. The novel cell therapy drug ICT19G1, submitted for approval by St. Science Biotech, has also been accepted by the Center for Drug Evaluation (CDE).

“GTJA Investment focuses on investments in the healthcare industry and places significant emphasis on its strategic layout in the CAR-T sector. We believe that St. George Biotech’s robust pipeline of innovative products has established a strong competitive barrier in this field, with considerable prospects for future development. Following the completion of this round of investment, GTJA Investment will fully leverage its industry resources and investment ecosystem to provide strong support for St. George Biotech’s future growth,” said Cai Dajian.

We hope that both parties, at the level of industry resources,

More Collaboration

Dr. Xiao Lei, Founder and Chairman of Stancell Biotech, stated that GTJA Investment, a renowned investment firm, is well-known for its focus and expertise in the healthcare and medical investment sector. “We highly appreciate GTJA Investment’s rigorous and pragmatic approach throughout the investment process. We are particularly impressed by the long-term dedication and in-depth research demonstrated by GTJA’s investment and industry research teams. We extend our gratitude to GTJA Investment and other investors for their recognition of Stancell Biotech’s technology and management team.”

Looking ahead to the long-term partnership with GTJA Investment, Dr. Xiao Lei expressed his hope that Stance Bio will deepen collaboration with GTJA Investment at the level of industry resources. By leveraging GTJA Investment’s extensive resources in the healthcare sector, both parties aim to continuously refine a synergistic ecosystem and make positive contributions to the healthcare field together.